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ABSTRACT
INTRODUCTION: Subarachnoid hemorrhage (SAH) is associated with high inhospital mortality and morbidity. 
Hyperglycemia occurs frequently in acute medical conditions including SAH and is associated with poor outcome. The 
aim of the study was to determine the frequency of Hyperglycemia in patients of subarachnoid hemorrhage. 
MATERIALS AND METHODS: This was a cross sectional study that was conducted from September 3, 2013 to March 
2, 2014 in Department of Neurology, Pakistan Institute of Medical Sciences, Islamabad. All patients who met the 
inclusion criteria were selected for the study. Subarachnoid hemorrhage was diagnosed on the basis of plain CT scan 
brain. Random blood sugar levels of all patients of SAH were checked with glucometer on the day of presentation. 
RESULTS: A total of 75 patients were included. The mean age of patients was 40.05 years with standard deviation of 
15.790 years. Out of 75 patients, 56 (74.67%) patients were male and 19 (25.33%) patients were female. 59 
(78.67%) patients with subarachnoid hemorrhage had hyperglycemia while 16 (21.33%) patients had no 
hyperglycemia.
CONCLUSION: In our study hyperglycemia is frequently found in patients of subarachnoid hemorrhage. Early detection 
and treatment of hyperglycemia should be a part of initial management so as to minimize the mortality.
O R I G I N A L  A R T I C L E
INTRODUCTION: Subarachnoid hemorrhage is an 
acute, critical medical emergency, with incidence of 9 
per 100,000 person- years. 85 % of cases of 
subarachnoid hemorrhage are due to rupture of 
cerebral aneurysms. Mortality for posterior circulation 
aneurysms is (10-15% for all aneurysms) higher as 
compared to anterior circulation aneurysms1. 
Clinical features of subarachnoid hemorrhage are 
severe and generalized, thunderclap headache, 
vomiting, neck stiffness, loss of consciousness, 
decerebrate posture, jerking of limbs or deficit of 
extremities2. Common complications are rebleed, 
hydrocephalus and reactive vasospasm3. Diagnosis 
can be made on CT brain, MRA is valuable with 96.7 % 
sensitivity in detection of intracranial aneurysm.4 
Definitive treatment is obliteration of aneurysm via 
endovascular procedures or surgical clipping1, external 
ventricular drains prevent secondary hydrocephalus5.
Hyperglycemia occurs frequently in aneurysmal 
subarachnoid hemorrhage and is associated with 
delayed cerebral ischemia and poor out come6. 
Worldwide various studies have identified the frequency 
and impact of hyperglycemia on the outcome in the 
patients of subarachnoid hemorrhage but very few local 
studies are available in even determining the frequency 
of this commonly prevalent condition in patients of 
subarachnoid hemorrhage. 
The aim of the study was to detect the frequency of 
hyperglycemia in patients of subarachnoid hemorrhage 
in our setup to generate the data in local population to 
emphasize checking the plasma glucose levels as a 
routine part of investigations in SAH.
 
MATERIALS AND METHODS:
This was a descriptive case study conducted in the 
Department of Neurology, Pakistan Institute of Medical 
Sciences, Islamabad for six months from September 3, 
2013 to March 02, 2013 after taking permission from 
ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
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outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
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outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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Table no: 1
Age distribution of patients in years
Total no of 
patients (n)
75
0
46.05
44.00
35
15.790
62
13
75
Valid
Missing
Mean age of patients in years
Median age of patients in years
Mode age of patients in years
Std. Deviation
Range age of patients in years
Minimum age of patients in years
Maximum age of patients in years
ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
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outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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Age group of patients
13-35 years of age 
group
36-55 years of age 
group
56-80 years of age 
group
Total
16
66.7%
25
78.1%
18
94.7%
59
78.7%
8
33.3%
7
21.9%
1
5.3%
16
21.3%
24
100.0%
32
100.0%
19
100.0%
75
100.0%
Hyperglycemia
Present Absent
0.083
Total p-value
ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
0 4P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
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increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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ethical committee of hospital. A total of 75 patients of 
subarachnoid hemorrhage were enrolled using non 
probability consecutive sampling. Sample size was 
calculated using WHO sample size calculator. An 
informed written consent was taken from all the 
patients. All patients of both genders above 13 years of 
age with subarachnoid hemorrhage (diagnosed on 
basis of CT scan brain) were enrolled in this study. 
Diagnostic criteria for SAH was defined on basis of CT 
scan brain if any one of the following is present on CT 
Brain: Hyperdensity (blood) in inter hemispheric fissure 
or sylvian fissure or perimesencephalic cistern with or 
without ventricular/parenchymal extension. 
Hyperglycemia was defined as Blood glucose levels 
>140 mg/dl checked with glucometer on the day of 
presentation.7 Those patients who had lobar 
(frontal/parietal/temporal/occipital regions of brain) or 
central (brainstem/basal ganglia/thalamus)  bleed on 
CT scan brain and Patients having prior history of 
diabetes mellitus were excluded from the study.
Patients who fulfilled the criteria as per the findings of 
CT scan brain underwent detailed history and 
Neurological examination. Random blood sugar levels 
of all the patients of subarachnoid hemorrhage were 
checked with glucometer on the day of presentation. 
The data was entered on a standardized Performa. Data 
was entered and analyzed using SPSS version 17. 
Mean and standard deviation was calculated for 
numerical variables (age). Frequencies and 
percentages were calculated for categorical variables 
(gender, hyperglycemia).
RESULTS:
A total of 75 patients were included in this study. The 
mean age of patients was 34.41±17.12.
The minimum age of patients was 13 years, maximum 
age was 75 years, median age of patients was 44 
years as shown in table 1:
RESULTS:
Out of 75 patients, 56 (74.67 %) patients were male 
and 19 (25.33%) patients were females as shown in 
Figure 1. 
Figure no: 1 Gender of patients
24 patients were in 13-35 years of age group, 32 
patients were in 36-55 years of age group and 19 
patients were in 56-80 years of age group as shown in 
figure 2: 
Figure no: 2
Distribution of patients in age groups
59 (78.67%) patients with subarachnoid hemorrhage 
had hyperglycemia while 16 (21.33%) patients did not 
have hyperglycemia as shown in figure no: 3
Figure no: 3
Hyperglycemia in patients with subarachnoid 
hemorrhage
16 patients in 13-35 years of age group had 
hyperglycemia while 8 patients had no hyperglycemia, 
25 patients in 36-55 years of age group had 
hyperglycemia while 7 patents had no hyperglycemia 
and 18 patients in 56-80 years of age group had 
hyperglycemia while 1 patient had no hyperglycemia 
insignificant p value of 0.083 showing insignificant 
age predilection as shown in table no: 2
43 male patients and 16 female patients had 
hyperglycemia while 13 male patients and 3 female 
patients had no hyperglycemia with insignificant p 
value of 0.495 as shown in figure no: 4
Figure no: 4
DISCUSSION:
Aneurysmal subarachnoid hemorrhage (SAH) is a 
devastating disease with high morbidity and mortality 
rates. Although these rates have decreased in the last 
decades, due to improving institutional care8, still the 
30 days case fatality rate is 35-45 percent so 
subarachnoid hemorrhage is an extremely fatal subtype 
of stroke.9 Prevention and treatment of neurologic 
complications such as rebleeding, hydrocephalus, and 
delayed cerebral ischemia (DCI) are obvious targets to 
improve prognosis and can be improved with 
multidisciplinary management approach10. Besides 
neurologic complications, patients with SAH often have 
non neurologic medical complications that can 
influence outcome such as neurocardiogenic injury, 
neurogenic pulmonary edema, hyperglycemia and 
electrolyte imbalance11. Hyperglycemia occurs 
frequently in aneurysmal subarachnoid hemorrhage and 
is associated with delayed cerebral ischemia and poor 
out come12. Several mechanisms have been proposed 
for hyperglycemia, one possible explanation is that 
following subarachnoid hemorrhage there is activation 
of hypothalamo-pituitary axis which in turn activates 
sympathetic nervous system leading to increase release 
of stress hormones enhancing glucose metabolism. 
Another possibility is activation of inflammatory 
response and release of cytokines which contribute to 
delayed cerebral ischemia3. Inpatient glucose levels 
above 7.8 mmol/litre (140 mg/dl) are associated with 
poor out come7. Plasma glucose levels during 
hospitalization predict the outcome of disease and can 
be effectively managed with insulin therapy13. 
Hyperglycemia is common in neurologic insults such as 
subarachnoid hemorrhage, traumatic brain injury and 
ischemic stroke, and associated with poor clinical 
outcome so intensive insulin therapy (IIT) has been 
suggested and used in these disorders.14 As treatment 
options are available for hyperglycemia , it has attracted 
increasing attention as a target for intervention, 
although adequate and safe glycemic control is difficult 
to achieve in patients with SAH. Because hyperglycemia 
seems to be implicated in the pathway from SAH to 
poor clinical outcome, insight into these mechanisms 
may reveal new treatment options.15-16
In our study, the mean age of patients was 46.05 years 
with standard deviation of 15.790 years. 56 (74.67%) 
patients were male and 19 (25.33%) patients were 
female and 78.67% patients of subarachnoid 
hemorrhage had hyperglycemia. These results of our 
study were comparable to the results of other studies. 
In a study conducted by Ghosh S et al17 showed that 
of the 1090 patients included in the study, 429 
(39.36%) were males. The mean age of the females 
was 4 years less than that of the males. Hyperglycemia 
at admission was termed as a serum glucose reading of 
>140 mg/dl on admission and 869 (74.22%) patients 
were found to have hyperglycemia at admission. 
Patients with hyperglycemia had 20.48% chance of a 
good outcome compared to a 64.85% chance of good 
outcome in patients with no hyperglycemia (P < 
0.0001). Patients with hyperglycemia at admission also 
had a higher risk of death (20.58%).
Kruyt ND et al18 included 17 cohort studies or clinical 
trials of 4095 patients with aneurysmal subarachnoid 
hemorrhage admitted within 72 hours that documented 
admission glucose levels or the rate of hyperglycemia. 
The mean admission glucose level was 9.3 mmol/L 
(range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) 
and the median proportion of patients with 
hyperglycemia was 69% (range, 29 to 100; 16 studies, 
3995 patients; cutoff levels of hyperglycemia, 5.7 to 
12.0 mmol/L). The pooled OR (8 studies, 2164 
patients) for poor outcome associated with 
hyperglycemia was 3.1 (range 2.3 to 4.3). Cutoff points 
for defining hyperglycemia varied across studies (6.4 to 
11.1 mmol/L), but this had no clear effect on the 
observed OR for poor outcome.
In another study conducted by Wartenberg KE et al19 
found that hyperglycemia (>11.1 mmol/L) was present 
in 30% of patients at admission. Other frequent medical 
complications observed were temperature >38.3 
degrees C (54%), followed by anemia (36%), 
hypertension (>160 mm Hg systolic; 27%), 
hypernatremia >150 mmol/L (22%), pneumonia 
(20%), hypotension (<90 mm Hg systolic, 18%), 
pulmonary edema (14%), and hyponatremia <130 
mmol/L (14%). Out of these abnormalities, Fever, 
anemia and hyperglycemia significantly predicted poor 
clinical outcome after adjustment for age, Hunt-Hess 
grade, aneurysm size, rebleeding, and cerebral 
infarction due to vasospasm.
Lanzino G et al20 studied plasma glucose level in 616 
patients admitted within 72 hours after SAH. Admission 
glucose levels showed a statistically significant 
association with Glasgow Coma Scale scores, volume of 
blood on computerized tomography (CT) scans, and 
level of consciousness at admission. Elevated glucose 
levels at admission correlated with poor outcome. A 
good recovery, as assessed by the Glasgow Outcome 
Scale at 3 months, occurred in 70.2% of patients with 
normal glucose levels (< or = 120 mg/dl) and in 53.7% 
of patients with hyperglycemia (> 120 mg/dl) (p = 
0.002). The death rates for these two groups were 
6.7% and 19.9%, respectively (p = 0.001). Increased 
glucose levels between Days 3 and 7 also predicted a 
poor outcome; in these sub groups, good recovery was 
observed in 132 (73.7%) of 179 patients who had 
normal glucose levels (< or = 120 mg/dl) and 160 
(49.7%) of 322 who had elevated glucose levels (> 
120 mg/dl) (p < 0.0001). Death occurred in 6.7% and 
20.8% of the two groups, respectively (p < 0.0001).
Badjatia N et al21 showed that mean admission blood 
glucose levels in higher range versus low range  (176.6 
+/- 40.3 mg/dL vs 162.3 +/- 47.8 mg/dL) and mean 
inpatient blood glucose values (166.2 +/- 24.7 mg/dL 
vs. 155.8 +/- 29.7 mg/dL) were significantly higher in 
patients with vasospasm( a potentially life threatening 
complication of sub arachnoid hemorrhage). 
Hyperglycemia was also associated with longer length of 
stay in the neurointensive care unit (14.5 +/- 7.1 days 
vs. 11.6 +/- 5.4 days) and poor outcome at discharge 
(modified Rankin score > or =3: 58.9% vs. 18.8%).
Our study has some limitations that need to be 
addressed. Determination of association of 
hyperglycemia with subarachnoid hemorrhage is sparse 
in literature and this study should be taken as an initial 
step in determining this association in our local 
population. Extrapolation of these data should therefore 
be done in the light of this limitation, although the 
results have shown that the relationship between 
hyperglycemia and SAH is robust and consistent. 
CONCLUSION:
In our study significant number of patients of 
subarachnoid hemorrhage had hyperglycemia at 
hospital admission and this association was found to be 
consistent. As hyperglycemia in acute subarachnoid 
hemorrhage is a potential risk factor of delayed cerebral 
ischemia and warrants poor clinical outcome so 
increased plasma glucose levels in previously 
normoglycemic patients of SAH should not go 
underrecognised. Further studies are needed to show 
the effect of hyperglycemia on poor outcome in SAH 
and for confirmation of potential benefit of adequate 
glycemic control after subarachnoid hemorrhage.
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